ShareBiotron BIT ANN 23/02/2021
Since September 2020 the Company has expanded its screening program to include a new series of recently designed
and synthesized compounds. These additional new compounds are progressing through a panel of cell-based
screening assays which are designed to identify the most potent, druggable compound(s) in the series. The screening
is progressing well and it is anticipated that a subset will soon be identified for progression to an animal model of the
Covid-19 disease.
Multiple hits on Covid
ShareBiotron BIT ANN 23/02/2021Biotron BIT ANN 23/02/2021
Since September 2020 the Company has expanded its screening program to include a new series of recently designed
and synthesized compounds. These additional new compounds are progressing through a panel of cell-based
screening assays which are designed to identify the most potent, druggable compound(s) in the series. The screening
is progressing well and it is anticipated that a subset will soon be identified for progression to an animal model of the
Covid-19 disease.
Multiple hits on Covid
Since September 2020 the Company has expanded its screening program to include a new series of recently designed
and synthesized compounds. These additional new compounds are progressing through a panel of cell-based
screening assays which are designed to identify the most potent, druggable compound(s) in the series. The screening
is progressing well and it is anticipated that a subset will soon be identified for progression to an animal model of the
Covid-19 disease.
Multiple hits on Covid
